UNASSIGNED: Systematic review was conducted using PubMed and Web of Science. The terms \"sleep apne\" and \"hypoxic burden\" were used to look for publications from the date of inception to August 15, 2023. Inclusion criteria: articles in English published in peer-reviewed journals. Exclusion criteria: (1) not available publications; (2) duplicated articles; (3) letters, editorials, and congress communications; (4) articles not including information about HB as a specific biomarker of OSA.
UNASSIGNED: 33 studies were included. The results were classified in 2 main sections: (1) HB implication in the CV sphere: HB showed to be a better predictor of CV risk in OSA patients than traditional measures such as AHI with possible clinical management implication in OSA. (2) HB response to OSA treatment: pharmacological and nonpharmacological treatments have demonstrated to be effective in improving hypoxia measured through the HB.
UNASSIGNED: HB could be a better and more effective parameter than traditional measurements in terms of diagnosis, risk prediction and therapeutic decisions in patients with OSA. This measure could be incorporated in sleep units and could play a role in OSA management, driving the clinic to a more personalized medicine.
■使用PubMed和WebofScience进行了系统评价。术语“睡眠apne”和“缺氧负担”用于寻找从开始之日起至2023年8月15日的出版物。纳入标准:在同行评审期刊上发表的英文文章。排除标准:(1)没有出版物;(2)重复文章;(3)信件,社论,和国会通讯;(4)文章不包括关于HB作为OSA特定生物标志物的信息。
■包括33项研究。结果分为2个主要部分:(1)CV领域中的HB含义:与传统措施(例如AHI)相比,HB对OSA患者的CV风险具有更好的预测作用,在OSA中可能具有临床管理意义。(2)HB对OSA治疗的反应:已证明药理学和非药理学治疗有效改善通过HB测量的缺氧。
■在诊断方面,HB可能是比传统测量更好,更有效的参数,OSA患者的风险预测和治疗决策。这项措施可以纳入睡眠单位,并可以在OSA管理中发挥作用,将诊所推向更个性化的医学。